Headlines

MID WEB AD_Vertical left side 426 pixels (height) x 170 pixels (width).gif

BPD/DS and SADI-S show comparable short-term outcomes as revisional procedures following RYGB

Both biliopancreatic diversion with duodenal switch (BPD/DS) or single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) show comparable short-term outcomes when performed as revisional procedures following RYGB. Although overall perioperative complications did not differ between groups, the approximately 6% anastomotic leak rate observed in both cohorts highlights the greater complexity and risk inherent to revisional bariatric surgery relative to primary ope

BPD/DS and SADI-S show comparable short-term outcomes as revisional procedures following RYGB

Rise in GLP-1 treatment for bariatric surgery-eligible patients

Bariatric surgery outperforms medical therapy for T2D across income levels

BPD/DS and SADI-S show comparable short-term outcomes as revisional procedures following RYGB

Research

Rise in GLP-1 treatment for bariatric surgery-eligible patients

According to researcher from Ohio State University Wexner Medical Center in Columbus, prescription for patients who were eligible for metabolic and bariatric surgery (MBS) for glucagon-like peptide-1 receptor agonist (GLP-1 RA) increased from 2018 to 2025, while MBS use decreased beginning in 2023. “To our knowledge, this is the first study to provide evidence that trends in MBS use have not yet stabilised through quarter 3 of 2025,” the researchers noted. “Stratification by

Bariatric surgery outperforms medical therapy for T2D across income levels

Nonmedical factors drive up to 60 percent of health outcomes, and for people with type 2 diabetes (T2D), social determinants of health factors like poverty, food insecurity, and unstable housing can derail even the best treatment plans. Now, a long-term study led by investigators at Joslin Diabetes Center finds that bariatric metabolic surgery is more effective at glycaemic and weight control than medical and lifestyle interventions for people with T2D, even in the setting of

Bariatric surgery facing upheaval amid growing GLP-1 use

At Roxborough Memorial Hospital in Philadelphia, surgeon Piotr Krecioch has his hands full launching a program offering surgical interventions to treat obesity. One in three Philadelphians are living with obesity, putting them at higher risk of chronic conditions like diabetes and heart disease, but these days fewer are seeking the bariatric surgical procedures long considered a leading medical treatment for the condition. "I'm trying to start a bariatric program at probably

Europe approves 7.2 mg injectable Wegovy for adults with obesity

The European Commission has granted final approval of a higher 7.2 mg maintenance dose of Wegovy (semaglutide) for adults who may need extra help losing weight. It is now approved in all 27 countries in the European Union. This gives doctors another option to help adults who need more weight loss after being on the 2.4 mg dose. The approval is based on a positive opinion from the European Medicines Agency’s scientific committee (CHMP) on 12 December 2025. The approval means t

Despite increase GLP-1s obesity rates are still rising

By 2030, nearly half of all American adults will have obesity, according to a study by researchers from the University of Virginia School of Medicine. In every single state, researchers expect at least 35% of adults to have a body mass index of 30 or higher, the threshold that defines obesity. That prediction may come as a shock, as weight loss medications like Wegovy and Zepbound become more popular and more affordable. The Centers for Disease Control and Prevention have bee

Obesity linked to one in 10 infections of deaths globally

Just over one in 10 deaths from a wide range of infectious diseases can be attributed to obesity worldwide, according to a major study led by a University College London (UCL) researcher. The study also reported people with obesity face a 70% higher risk of hospitalisation or death from an infection than those of a healthy weight. Obesity can increase the risk posed by many different infectious diseases, from flu and COVID-19 to stomach bugs and urinary tract infections, and

Study raises concerns over long-term effectiveness of GLP-1s

Researchers have found that people regain weight faster after quitting these GLP-1s compared with after diet and exercise alone. Improvements in heart health and diabetes risk also tend to reverse within a few years. The results suggest long-term success may require more than medication alone. The findings call into question how durable these treatments really are. On average, individuals regained about 0.4 kilograms per month after stopping medication. Based on these trends

Overweight and obesity-linked cardiovascular deaths increasing in young Australians

Higher rates of death among younger Australians from cardiovascular disease has been linked to being overweight or obese, a study by researchers at the University of Melbourne has reported. The study looked at premature overweight and obesity-related cardiovascular disease mortality for people aged between 35–74 years. Professor Tim Adair, a demographer in the Nossal Institute for Global Health at the University of Melbourne, used Australian Bureau of Statistics death certifi

BPD/DS and SADI-S show comparable short-term outcomes as revisional procedures following RYGB

Positive Phase II results for Genentech’s dual GLP-1/GIP CT-388 for obesity

Genentech announced positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the treatment of obesity. The study found that once-weekly subcutaneous injections of CT-388 (titrated up to 24 mg) resulted in significant and clinically meaningful placebo-adjusted weight loss of 22.5% (efficacy estimand) without reaching a weight loss plateau at 48 weeks. CT-388 aims to reduce appetite and

Ring-augmented SG betters standard SG for greater weight-loss durability at 36 months

Ring-augmented sleeve gastrectomy (Ra-SG) achieved statistically greater weight-loss durability at 36 months compared with standard sleeve gastrectomy (SG), according to the outcomes from a randomised clinical trial by researchers from Egypt. They also reported that Ra-SG has a lower incidence of clinically significant RWG and smaller gastric pouch volumes at three years. According to the authors, although Ra-SG has the potential to improve SG by placing a non-adjustable ring

First participants dosed in Ascletis’ 13-week US Phase II Study for ASC30

The first participants have been dosed in Ascletis Pharma’s US 13-week Phase II study with ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of type 2 diabetes mellitus. Topline data from the Phase II study are expected in the third quarter of 2026. Ascletis recently completed a 13-week Phase II study evaluating ASC30 for the treatment of obesity in 125 participants with obesity or overweight with at least one weight-related comorbidity at multip

Industry

Europe approves 7.2 mg injectable Wegovy for adults with obesity

FDA approves Novo Nordisk's oral GLP-1 for weight loss

Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues

First patient treated in EASE clinical trial evaluating the EndoZip Automated Suturing System for ESG

All caught up?

See all news

New: Directory

Discover global suppliers of specialist bariatric services, treatments, products, and medical equipment.

Browse directory

Events

14th Congress of the European Chapter of the International Federation for the Surgery and Other Therapies For Obesity

View details

1 September 2026

XXIX IFSO World Congress

View details

3 December 2025

8TH Gulf Obesity Surgery Society International Conference

View details

Headlines

BPD/DS and SADI-S show comparable short-term outcomes as revisional procedures following RYGB

BPD/DS and SADI-S show comparable short-term outcomes as revisional procedures following RYGB

Rise in GLP-1 treatment for bariatric surgery-eligible patients

Bariatric surgery outperforms medical therapy for T2D across income levels

BPD/DS and SADI-S show comparable short-term outcomes as revisional procedures following RYGB

Research

Rise in GLP-1 treatment for bariatric surgery-eligible patients

Bariatric surgery outperforms medical therapy for T2D across income levels

Bariatric surgery facing upheaval amid growing GLP-1 use

Europe approves 7.2 mg injectable Wegovy for adults with obesity

Despite increase GLP-1s obesity rates are still rising

Obesity linked to one in 10 infections of deaths globally

Study raises concerns over long-term effectiveness of GLP-1s

Overweight and obesity-linked cardiovascular deaths increasing in young Australians

BPD/DS and SADI-S show comparable short-term outcomes as revisional procedures following RYGB

Positive Phase II results for Genentech’s dual GLP-1/GIP CT-388 for obesity

Ring-augmented SG betters standard SG for greater weight-loss durability at 36 months

First participants dosed in Ascletis’ 13-week US Phase II Study for ASC30

Industry

Europe approves 7.2 mg injectable Wegovy for adults with obesity

FDA approves Novo Nordisk's oral GLP-1 for weight loss

Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues

First patient treated in EASE clinical trial evaluating the EndoZip Automated Suturing System for ESG

All caught up?

New: Directory

Discover global suppliers of specialist bariatric services, treatments, products, and medical equipment.

Events

(See all)

4th IFSO MENAC Meeting

BOMSS ASM 2026

6th London International Bariatric Surgery Symposium (LIBSS)

2026 IBC University of Oxford World Congress

14th Congress of the European Chapter of the International Federation for the Surgery and Other Therapies For Obesity

XXIX IFSO World Congress

8TH Gulf Obesity Surgery Society International Conference

Tweets

Back to Top